A plain language summary of the TROPiCS-02 study: impact of sacituzumab govitecan on quality of life in patients with HR-positive/HER2-negative breast cancer

This Plain Language Summary of Publication article (PLSP) from Future Oncology, investigated sacituzumab govitecan (TRODELVY^®) for treating HR-positive/HER2-negative advanced or metastatic breast cancer. This type of breast cancer grows in response to hormones but has low HER2 levels. The study included 776 participants who were randomly assigned to receive either sacituzumab govitecan or standard chemotherapy. Results showed that sacituzumab govitecan helped patients live longer and delayed cancer progression compared to chemotherapy. This summary focuses on the quality-of-life findings from the study, which can help patients and doctors make informed treatment decisions.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial’ and was published in The Oncologist.

Visit Oxford Academic using the link to read the original article.

• antibody–drug conjugate
• breast cancer
• HER2-negative
• HR-positive
• lay summary
• plain language summary
• quality of life